Canagliflozin for Type 2 Diabetes - reduces cardiovascular events.
Canagliflozin reduces major adverse cardiovascular events (MACE) in patients with T2DM. Big paper in the NEJM, (the trials sponsored by Janssen Research, but independently authored), showing a reduction in a composite of: death from cardiovascular causes, non-fatal myocardial infarction non-fatal stroke with canagliflozin. It was a small effect, (in medical terminology only just significant) but relevant to many patients with diabetes; the trials were really to prove CV safet
